The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …

Introduction: Obesity is a growing threat to public health, increasing risks of numerous
diseases and mortality, and impairing quality of life. If current trends continue, more than 1.1 …

Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in
the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and
obesity for their high efficacy in controlling glycaemia and inducing body weight loss …

Aim We evaluated gastrointestinal (GI) adverse events (AEs) with once‐weekly semaglutide
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …

Background Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM)
and chronic weight management in obesity or overweight adults. However, real-world data …

Objectives: This study aims to explore the weight loss effect and safety of semaglutide as a
conventional anti-obesity drug systematically in obese or overweight patients without …

Aim To explore the safety and efficacy of subcutaneous semaglutide 2.4 mg, administered
once a week in non‐diabetic overweight or obese individuals. Methods A thorough search …

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are effective treatments for type 2
diabetes as they stimulate insulin release and promote weight loss through appetite …

Background: Body weight (BW) loss is an essential therapeutic goal in type 2 diabetes
(T2D). Glucagon-like peptide-1 receptor agonists are effective in reducing BW, but their …